PharMerica (NYSE: PMC) is expected to report Q1 earnings on May 1. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict PharMerica's revenues will compress -12.8% and EPS will grow 13.3%.

The average estimate for revenue is $435.1 million. On the bottom line, the average EPS estimate is $0.34.

Revenue details
 Last quarter, PharMerica booked revenue of $433.2 million. GAAP reported sales were 13% lower than the prior-year quarter's $495.6 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $0.33. GAAP EPS of $0.13 for Q4 were 50% lower than the prior-year quarter's $0.26 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 17.3%, 210 basis points better than the prior-year quarter. Operating margin was 4.5%, 50 basis points better than the prior-year quarter. Net margin was 0.9%, 70 basis points worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $1.66 billion. The average EPS estimate is $1.40.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 122 members out of 128 rating the stock outperform, and six members rating it underperform. Among 20 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 18 give PharMerica a green thumbs-up, and two give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on PharMerica is outperform, with an average price target of $15.29.

Is PharMerica the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.